On June 24, Charles River Laboratories rose 6.55% in regular trading, trading at $199.875/share, with turnover of approximately $32.04 million. The rally was driven by a confluence of Morgan Stanley's rating upgrade and positive signals from the company's fiscal year earnings conference.

Morgan Stanley upgraded Charles River from equal weight to overweight, raising the price target from $185 to $220. According to FactSet, the average analyst price target stands at $220.29, suggesting further upside from the current trading level. The stock initially rose over 1% on the upgrade announcement last week.

At the recently held fiscal year earnings conference, Chairman and CEO James Foster highlighted sustained improvement in book-to-bill ratios since Q3, noting that the biotech funding environment has significantly improved — with October marking the second-best month for biotech financing in history. Management emphasized that the prior 18-month period of weak biotech demand was primarily driven by constrained capital access, and the current funding recovery is now propelling demand growth. Large pharma demand remains stable, supported by long-term contracts, though insufficient to fully offset prior biotech weakness.

Within the Life Sciences Tools & Services sector, gains were broad-based, with Illumina up 6.15%, Danaher up 4.36%, Mettler-Toledo up 4.33%, and Thermo Fisher Scientific up 3.92%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)